Hosokawa et al. compared another serological marker, sPan-1, which is a pancreatic adenocarcinoma antigen, to other serological markers, such as CA19-9, carcinoembryonic antigen (CEA), and duke pancreatic monoclonal antigen type 2 (DUPAN-2), in the recurrence of early stages of pancreatic adenocarcinoma. This evidence concerns the gene CEACAM5 and pancreatic adenocarcinoma.